Additional supporting information may be found in the online version of this article at the publisher's web-site.


Figure S1. Relationship between CrCl and canakinumab clearance (estimated by the PK-binding model using the post hoc option of NONMEM) in gouty arthritis patients (line represents the fitting by a power function). CrCl, creatinine clearance; PK, pharmacokinetic.

Table S1. Summary of Canakinumab Clinical Study Designs

Table S2. Summary of Baseline Demographic Parameters

Table S3. Institutional Review Board or Ethics Committee Listings by Center Number

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.